{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:28Z","timestamp":1786982788132,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40292-017-0242-z","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:04:52Z","timestamp":1512173092000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension"],"prefix":"10.1007","volume":"25","author":[{"name":"on behalf of the THYPERevolution Steering Committee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0635-4921","authenticated-orcid":false,"given":"Giuliano","family":"Tocci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Calcullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Vincenzo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Lonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Orselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Scuteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Vulpis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Acone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Zaninelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"issue":"9","key":"242_CR1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1751-7176.2010.00322.x","volume":"12","author":"P Bramlage","year":"2010","unstructured":"Bramlage P, Bohm M, Volpe M, Khan BV, Paar WD, Tebbe U, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12(9):666\u201377.","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"242_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","volume":"218","author":"C Borghi","year":"2016","unstructured":"Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. 2016;218:83\u20138.","journal-title":"Int J Cardiol"},{"issue":"8","key":"242_CR3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/HJH.0b013e328348efa7","volume":"29","author":"C Prugger","year":"2011","unstructured":"Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011;29(8):1641\u20138.","journal-title":"J Hypertens"},{"issue":"4","key":"242_CR4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/jhh.2016.71","volume":"31","author":"G Tocci","year":"2017","unstructured":"Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258\u201362.","journal-title":"J Hum Hypertens"},{"issue":"11","key":"242_CR5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/jhh.2015.4","volume":"29","author":"G Tocci","year":"2015","unstructured":"Tocci G, Ferrucci A, Pontremoli R, Ferri C, Rosei EA, Morganti A, et al. Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000\u20132005 and 2005\u20132011 hypertension surveys. J Hum Hypertens. 2015;29(11):696\u2013701.","journal-title":"J Hum Hypertens"},{"issue":"10060","key":"242_CR6","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","volume":"388","author":"MH Olsen","year":"2016","unstructured":"Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665\u2013712.","journal-title":"Lancet"},{"issue":"1","key":"242_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00151642-200815010-00003","volume":"15","author":"M Volpe","year":"2008","unstructured":"Volpe M, Erhardt LRW, Williams B. Cardiovascular risk management in clinical practice: time to change. High Blood Press Cardiovasc Prev. 2008;15(1):9\u201316.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"8","key":"242_CR8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/HJH.0000000000000988","volume":"34","author":"J Redon","year":"2016","unstructured":"Redon J, Mourad JJ, Schmieder RE, Volpe M, Weiss TW. Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34(8):1480\u20138.","journal-title":"J Hypertens."},{"issue":"7","key":"242_CR9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281\u2013357.","journal-title":"J Hypertens"},{"issue":"1","key":"242_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40292-013-0007-2","volume":"20","author":"M Volpe","year":"2013","unstructured":"Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1):45\u201352.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"2","key":"242_CR11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00003495-198325020-00002","volume":"25","author":"RE Kates","year":"1983","unstructured":"Kates RE. Calcium antagonists. Pharmacokinetic properties. Drugs. 1983;25(2):113\u201324.","journal-title":"Drugs."},{"issue":"2","key":"242_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-198325020-00001","volume":"25","author":"TT Zsoter","year":"1983","unstructured":"Zsoter TT, Church JG. Calcium antagonists. Pharmacodynamic effects and mechanism of action. Drugs. 1983;25(2):93\u2013112.","journal-title":"Drugs."},{"issue":"2","key":"242_CR13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2165\/00003495-198325020-00005","volume":"25","author":"P Theroux","year":"1983","unstructured":"Theroux P, Taeymans Y, Waters DD. Calcium antagonists. Clinical use in the treatment of angina. Drugs. 1983;25(2):178\u201395.","journal-title":"Drugs."},{"issue":"2","key":"242_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2165\/00003495-198325020-00004","volume":"25","author":"C Spivack","year":"1983","unstructured":"Spivack C, Ocken S, Frishman WH. Calcium antagonists. Clinical use in the treatment of systemic hypertension. Drugs. 1983;25(2):154\u201377.","journal-title":"Drugs."},{"issue":"2","key":"242_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00003495-198325020-00003","volume":"25","author":"BN Singh","year":"1983","unstructured":"Singh BN, Nademanee K, Baky SH. Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs. 1983;25(2):125\u201353.","journal-title":"Drugs."},{"issue":"4","key":"242_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/08037059609079672","volume":"5","author":"T Toyo-Oka","year":"1996","unstructured":"Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press. 1996;5(4):206\u20138.","journal-title":"Blood Press"},{"issue":"4","key":"242_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003495-199855040-00003","volume":"55","author":"TF Luscher","year":"1998","unstructured":"Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs. 1998;55(4):509\u201317.","journal-title":"Drugs."},{"issue":"17","key":"242_CR18","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2165\/00003495-200464170-00011","volume":"64","author":"K McKeage","year":"2004","unstructured":"McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923\u201340.","journal-title":"Drugs."},{"issue":"12","key":"242_CR19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2165\/00003495-200161120-00010","volume":"61","author":"SM Cheer","year":"2001","unstructured":"Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs. 2001;61(12):1777\u201399.","journal-title":"Drugs."},{"issue":"2","key":"242_CR20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-199244020-00008","volume":"44","author":"PA Todd","year":"1992","unstructured":"Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44(2):251\u201377.","journal-title":"Drugs."},{"issue":"4","key":"242_CR21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00003495-198836040-00002","volume":"36","author":"E Saltiel","year":"1988","unstructured":"Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1988;36(4):387\u2013428.","journal-title":"Drugs."},{"issue":"4","key":"242_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2165\/00003495-198733040-00002","volume":"33","author":"EM Sorkin","year":"1987","unstructured":"Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987;33(4):296\u2013345.","journal-title":"Drugs."},{"issue":"Suppl 4","key":"242_CR23","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00005344-199117040-00003","volume":"17","author":"ST Hall","year":"1991","unstructured":"Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol. 1991;17(Suppl 4):S9\u201313.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"242_CR24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00132580-200111000-00008","volume":"3","author":"M Epstein","year":"2001","unstructured":"Epstein M. Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 2001;3(6):398\u2013407.","journal-title":"Heart Dis."},{"key":"242_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/080370598438999","volume":"1","author":"PA Zwieten van","year":"1998","unstructured":"van Zwieten PA. Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist. Blood Press Suppl. 1998;1:5\u20138.","journal-title":"Blood Press Suppl"},{"issue":"3","key":"242_CR26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2165\/00003495-199550030-00009","volume":"50","author":"M Haria","year":"1995","unstructured":"Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50(3):560\u201386.","journal-title":"Drugs."},{"issue":"2","key":"242_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14779072.3.2.207","volume":"3","author":"CS Liau","year":"2005","unstructured":"Liau CS. Barnidipine: a new calcium channel blocker for hypertension treatment. Expert Rev Cardiovasc Ther. 2005;3(2):207\u201313.","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"12","key":"242_CR28","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.clinthera.2009.12.011","volume":"31","author":"C Palombo","year":"2009","unstructured":"Palombo C, Malshi E, Morizzo C, Rakebrandt F, Corretti V, Santini F, et al. Arterial wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension. Clin Ther. 2009;31(12):2873\u201385.","journal-title":"Clin Ther"},{"issue":"28","key":"242_CR29","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219.","journal-title":"Eur Heart J"},{"issue":"12","key":"242_CR30","doi-asserted-by":"crossref","first-page":"e52145","DOI":"10.1371\/journal.pone.0052145","volume":"7","author":"CR Elley","year":"2012","unstructured":"Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al. The efficacy and tolerability of \u2018polypills\u2019: meta-analysis of randomised controlled trials. PLoS ONE. 2012;7(12):e52145.","journal-title":"PLoS ONE"},{"issue":"7","key":"242_CR31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","volume":"29","author":"H Makani","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate\u2013a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270\u201380.","journal-title":"J Hypertens"},{"issue":"10","key":"242_CR32","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1097\/00004872-200410000-00001","volume":"22","author":"FH Messerli","year":"2004","unstructured":"Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens. 2004;22(10):1845\u20137.","journal-title":"J Hypertens"},{"issue":"5","key":"242_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ajh.2008.17","volume":"21","author":"MH Alderman","year":"2008","unstructured":"Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21(5):493\u20139.","journal-title":"Am J Hypertens"},{"issue":"5","key":"242_CR34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/ajh.2011.8","volume":"24","author":"G Tocci","year":"2011","unstructured":"Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011;24(5):582\u201390.","journal-title":"Am J Hypertens"},{"issue":"9080","key":"242_CR35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757\u201364.","journal-title":"Lancet"},{"issue":"9192","key":"242_CR36","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751\u20136.","journal-title":"Lancet"},{"issue":"9227","key":"242_CR37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","volume":"356","author":"MJ Brown","year":"2000","unstructured":"Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366\u201372.","journal-title":"Lancet"},{"issue":"3","key":"242_CR38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08037050310009545","volume":"12","author":"E Malacco","year":"2003","unstructured":"Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003;12(3):160\u20137.","journal-title":"Blood Press"},{"issue":"9227","key":"242_CR39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359\u201365.","journal-title":"Lancet"},{"issue":"16","key":"242_CR40","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"HR Black","year":"2003","unstructured":"Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073\u201382.","journal-title":"JAMA"},{"issue":"21","key":"242_CR41","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805\u201316.","journal-title":"JAMA"},{"issue":"6","key":"242_CR42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/08037050903450468","volume":"18","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308\u201347.","journal-title":"Blood Press"},{"issue":"23","key":"242_CR43","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative. Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981\u201397.","journal-title":"JAMA"},{"issue":"9489","key":"242_CR44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"242_CR45","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"242_CR46","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","volume":"23","author":"L Liu","year":"2005","unstructured":"Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157\u201372.","journal-title":"J Hypertens"},{"key":"242_CR47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/080370598438546","volume":"1","author":"L Argenziano","year":"1998","unstructured":"Argenziano L, Izzo R, Iovino G, De Luca N, Parrella L, Morisco C, et al. Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients. Blood Press Suppl. 1998;1:9\u201314.","journal-title":"Blood Press Suppl"},{"issue":"3","key":"242_CR48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.curtheres.2008.06.002","volume":"69","author":"G Rossetti","year":"2008","unstructured":"Rossetti G, Pizzocri S, Brasca F, Pozzi M, Beltrami LM, Bolla GB, et al. Antihypertensive effect of barnidipine 10\u00a0mg or amlodipine 5 to 10\u00a0mg once daily in treatment-naive patients with essential hypertension: a 24-week, randomized, open-label, pilot study. Curr Ther Res Clin Exp. 2008;69(3):192\u2013206.","journal-title":"Curr Ther Res Clin Exp."},{"issue":"7","key":"242_CR49","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.clinthera.2010.06.021","volume":"32","author":"G Parati","year":"2010","unstructured":"Parati G, Giglio A, Lonati L, Destro M, Ricci AR, Cagnoni F, et al. Effectiveness of barnidipine 10 or 20\u00a0mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther. 2010;32(7):1270\u201384.","journal-title":"Clin Ther"},{"issue":"4","key":"242_CR50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1179\/2295333715Y.0000000012","volume":"70","author":"R Lins","year":"2015","unstructured":"Lins R, Marckx P, Vandebeek R, Vanhoutvinck C, Neuville O. Barnidipine real-life tolerability in arterial hypertension: results from the BASIC-HT study. Acta Clin Belg. 2015;70(4):244\u201350.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"242_CR51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40292-016-0177-9","volume":"24","author":"R Lins","year":"2017","unstructured":"Lins R, Haerden Y, de Vries C. Replacement of amlodipine and lercanidipine by barnidipine: tolerability and effectiveness in a real-life study. High Blood Press Cardiovasc Prev. 2017;24(1):29\u201336.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"3","key":"242_CR52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.curtheres.2008.06.003","volume":"69","author":"F Angeli","year":"2008","unstructured":"Angeli F, Repaci S, Borgioni C, Sardone M, Scotti A, Verdecchia P. Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: a 12-week, open-label noncomparison study. Curr Ther Res Clin Exp. 2008;69(3):207\u201320.","journal-title":"Curr Ther Res Clin Exp."},{"key":"242_CR53","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.1038\/srep12603","volume":"5","author":"G Derosa","year":"2015","unstructured":"Derosa G, Mugellini A, Querci F, Franzetti I, Pesce RM, D\u2019Angelo A, et al. Barnidipine or lercanidipine on echocardiographic parameters in hypertensive, type 2 diabetics with left ventricular hypertrophy: a randomized clinical trial. Sci Rep. 2015;5:12603.","journal-title":"Sci Rep."},{"key":"242_CR54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12872-016-0237-z","volume":"16","author":"G Derosa","year":"2016","unstructured":"Derosa G, Mugellini A, Pesce RM, D\u2019Angelo A, Maffioli P. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord. 2016;16:66.","journal-title":"BMC Cardiovasc Disord."},{"issue":"4","key":"242_CR55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08037051.2011.561072","volume":"20","author":"ML Muiesan","year":"2011","unstructured":"Muiesan ML, Salvetti M, Belotti E, Paini A, Rosei CA, Aggiusti C, et al. Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients. Blood Press. 2011;20(4):244\u201351.","journal-title":"Blood Press"}],"container-title":["High Blood Pressure &amp; Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-017-0242-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-017-0242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-017-0242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T23:12:51Z","timestamp":1520464371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-017-0242-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s40292-017-0242-z","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,2]]}}}